ReviewClinical microbiology reviews2025
Lessons learned from successful implementation of tetanus and diphtheria vaccination programs.
Review in Clinical microbiology reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
SUMMARYVaccines against tetanus and diphtheria are known as "legacy" vaccines because they were developed in the 1920s, long before the establishment of modern immunology and at a time when the Food & Drug Administration (FDA) was still in its infancy. Despite lacking the technological advances of today, these medical interventions represent two of the most successful vaccines ever developed, as indicated by the incidence of disease falling to less than one case of tetanus per 10 million person-years and approximately one case of diphtheria per 1 billion person-years in the U.S. population. Here, we compare the success of the tetanus and diphtheria vaccination programs to that of other common childhood vaccines and review an evidence-based approach to adult booster vaccination schedules. These findings indicate that after completing the childhood vaccination series, decennial booster vaccinations may no longer be needed to maintain protective immunity in the general population. Moreover, updating the current vaccination program to remove adult decennial booster doses will not only harmonize the U.S. recommendations with the guidelines of the World Health Organization (WHO) but may also further improve the risk:benefit ratio for vaccination while providing up to $1 billion annually in healthcare savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.